Back to top
more

Allurion Technologies, Inc. (ALUR)

(Delayed Data from NYSE)

$2.77 USD

2.77
21,314

-0.01 (-0.54%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.76 -0.01 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Flora Growth Corp. (FLGC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Flora Growth (FLGC) delivered earnings and revenue surprises of -83.33% and +25.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of -60.00% and -17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

by Zacks Equity Research

Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Watch From a Challenging Industry

by Indrajit Bandyopadhyay

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

Zacks Equity Research

Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates

by Zacks Equity Research

Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of 128.10% and 2.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.56% and 5.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 39.84% and 5.54%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Evolus (EOLS) delivered earnings and revenue surprises of -80% and 4.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy From a Challenging Industry

by Indrajit Bandyopadhyay

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.

Zacks Equity Research

Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of -40% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -41.38% and 0.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medtronic (MDT) Tops Q3 Earnings Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 2.21% and 0.43%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

by Zacks Equity Research

The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 77.78% and 21.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 51.85% and 8.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ALUR Stock Declines Despite Submitting PMA for Allurion Balloon

by Zacks Equity Research

Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.

Zacks Equity Research

Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy

by Zacks Equity Research

Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.

Zacks Equity Research

Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.